Research Identifies Protein Driving Prostate Cancer Chemotherapy Resistance

A study in Cellular and Molecular Life Sciences identified Claudin-1 (CLDN1) as a key protein enabling prostate cancer cells to resist chemotherapy. CLDN1 facilitates neuroendocrine transdifferentiation, a process where cancer cells become treatment-resistant. Depleting CLDN1 in models reduced this shift and resistance to docetaxel, offering a potential new therapeutic target.